Predict your next investment

Immune Pharmaceuticals company logo
Corporation
HEALTHCARE | Biotechnology
immunepharma.com

See what CB Insights has to offer

Partners & Customers

6

About Immune Pharmaceuticals

Immune Pharmaceuticals is a biopharmaceutical company developing therapeutic agents for the treatment of immunologic and inflammatory diseases.

Immune Pharmaceuticals Headquarter Location

1 Bridge Plaza N Suite 270

Fort Lee, New Jersey, 07024,

United States

201-464-2677

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Immune Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Immune Pharmaceuticals Rank

Latest Immune Pharmaceuticals News

Diabetic Peripheral Neuropathy Treatment Market – Careful Account Of Growth Drivers, Trends, Opportunities, And Challenges Impacting By 2025

Feb 4, 2020

Diabetic Peripheral Neuropathy Treatment Market (6 Forces Forecast 2019-2025) research report offers in-intensity insight of the Diabetic Peripheral Neuropathy Treatment industry masking all vital parameters along with Marketing Channel, Direct Marketing, Indirect Marketing, Brand Strategy, Pricing Strategy, Market Positioning, Target Client, and Distributors/Traders List. Diabetic Peripheral Neuropathy Treatment Market report includes an extensive analysis of competition by topmost prime manufacturers (Achelios Therapeutics Inc, Celgene Corp, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals Inc, KPI Therapeutics Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Novaremed Ltd, Reata Pharmaceuticals Inc, Relief Therapeutics Holding AG, ViroMed Co Ltd) which providing information such as Company Profiles, Product Revenue, Market Size, Trade, Sales Volume, and Industry Share by Type, Specifications and Contact Information. The Diabetic Peripheral Neuropathy Treatment market report also reviews industry segments and sub-segments, along with production technology, types of product, application and market verticals. Get Free Sample PDF (including full TOC, Tables and Figures) of Diabetic Peripheral Neuropathy Treatment [email protected]   https://www.researchmoz.us/enquiry.php?type=S&repid=2251608    Diabetic Peripheral Neuropathy Treatment Market Target Audience Production Companies, Suppliers, Channel Partners, Marketing Authorities, Subject Matter Experts, Research Institutions, Financial Institutions, Market Consultants, Government Authorities. Scope of Diabetic Peripheral Neuropathy Treatment Market:  The Diabetic Peripheral Neuropathy Treatment market report analyzes the opportunities in the global market, analyzing the data on a historical basis, estimated data for 2019, and forecasted data till the year 2025. Market analysis includes data in terms of both, value (US$) and volume (MT). The market outlook of the Diabetic Peripheral Neuropathy Treatment market report covers feed industry overview, global Diabetic Peripheral Neuropathy Treatment industry outlook, macroeconomic outlook, and forecasted factors. On the basis of product, this report displays the sales volume, revenue (Million USD), product price, Diabetic Peripheral Neuropathy Treatment market share and growth rate of each type, primarily split into- Antimunocel Geographically, the report includes the research on production, consumption, revenue, Diabetic Peripheral Neuropathy Treatment market share and growth rate, and forecast (2019-2025) of the following regions: United States, China, Japan, India, Other Regions Europe (Germany, UK, France, Italy, Spain, Russia, Poland) Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam) Central and South America (Brazil, Mexico, Colombia) Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria) Key Questions Answered in the Report: How is the Diabetic Peripheral Neuropathy Treatment market expected to Grow In Terms Of Value during the study period? What are the Competition Developments and Trends in the Diabetic Peripheral Neuropathy Treatment market? What are the underlying Macro-Economic and Industry Factors impacting the growth of the Diabetic Peripheral Neuropathy Treatment market? What are the Key Challenges, Opportunities, and Improvements faced by market players in the global Diabetic Peripheral Neuropathy Treatment market? Contact:

Immune Pharmaceuticals Acquisitions

1 Acquisition

Immune Pharmaceuticals acquired 1 company. Their latest acquisition was EpiCept on August 26, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/26/2013

Other Venture Capital

$99M

$66.85M

Merger

1

Date

8/26/2013

Investment Stage

Other Venture Capital

Companies

Valuation

$99M

Total Funding

$66.85M

Note

Merger

Sources

1

Immune Pharmaceuticals Partners & Customers

6 Partners and customers

Immune Pharmaceuticals has 6 strategic partners and customers. Immune Pharmaceuticals recently partnered with WuXi Biologics on July 7, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

7/9/2018

Partner

China

2

6/16/2017

Licensor

United States

Subscribe to see more

Subscribe to see more

10

6/29/2015

Licensor

Israel

Subscribe to see more

Subscribe to see more

10

5/4/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

4/29/2011

Licensor

Canada

Subscribe to see more

Subscribe to see more

10

Date

7/9/2018

6/16/2017

6/29/2015

5/4/2015

4/29/2011

Type

Partner

Licensor

Licensor

Partner

Licensor

Business Partner

Country

China

United States

Israel

United States

Canada

News Snippet

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Immune Pharmaceuticals Team

2 Team Members

Immune Pharmaceuticals has 2 team members, including former Chief Executive Officer, Tony Fiorino.

Name

Work History

Title

Status

Tony Fiorino

Chief Executive Officer

Former

John Clark

Controller

Former

Name

Tony Fiorino

John Clark

Work History

Title

Chief Executive Officer

Controller

Status

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.